Mario Romeo | Precision Medicine | Best Researcher Award

Published on 02/07/202502/07/2025 by Top Pharmaceutical

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, Università degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania “Luigi Vanvitelli” 🎓, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease 🏥, and metabolic dysfunction. A recipient of over 20 international awards 🏆, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication Profile

Orcid

Education

Dr. Mario Romeo 🎓 began his academic journey with honors, earning his Diploma di Maturità Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode 📜. He continued his excellence at the University of Campania “Luigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo 🏅 has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 🎓 and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes 🏆 at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary “CoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research Focus

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions 🥗🧠💊. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis

Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review

Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot?

Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications

Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?

Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?

FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis

Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report

Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?

Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

Jian Shi | Precision Medicine | Best Researcher Award

Published on 10/06/202510/06/2025 by Top Pharmaceutical

Jian Shi | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Jian Shi, Neurology of UCSF, United States

Assoc. Prof. Dr. Jian Shi is a distinguished neuroscientist at the University of California, San Francisco, with a Ph.D. in Neurobiology from Navy Medical University, China. 🧬 He completed postdoctoral training at the University of Texas Southwestern Medical Center, focusing on neuroscience. His research integrates brain injury, neurodegenerative diseases, and glioblastoma with cutting-edge AI and bioinformatics tools. 🧪🧠 Dr. Shi has authored highly cited publications and received numerous accolades, including the APS Outstanding Paper Award. 🌟 A dedicated mentor and educator, he actively contributes to diversity and public service in neurology and biomedical research.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Jian Shi began his academic journey at the National University of Defense Technology in Hunan Province, China, earning both his B.S. and M.S. degrees in Biomechanics. ⚙️📘 He then pursued his Ph.D. in Neurobiology under the mentorship of Dr. Lu Changlin at the prestigious Navy Medical University in Shanghai. 🧬🏥 Driven by a passion for neuroscience, he completed his postdoctoral training at the University of Texas Southwestern Medical Center under the guidance of Dr. Steven G. Kernie, focusing on advanced neuroscience research. 🧠🔬 His academic foundation bridges biomechanics and cutting-edge neurobiological science.

Awards

Assoc. Prof. Dr. Jian Shi has received numerous accolades recognizing his excellence in research and education. 🇨🇳 He was honored with the prestigious National Award for Scientific Progress, Level 2 in China 🥇🔬 and received the Award for Outstanding Scientists from Navy Medical University, where he also earned the Best Teacher Award for his commitment to academic excellence 👨‍🏫🌟. His groundbreaking work earned him the “Top 50 Most Cited Article Award” from the Journal of Clinical Medicine 📖📈 and the APS Outstanding Paper Award from Acta Pharmacologica Sinica 🧪🏅. He is also recognized as a Trusted Reviewer by the International Journal of Molecular Sciences 🧠✅.

Research Focus

Assoc. Prof. Dr. Jian Shi’s research centers around neurobiology, with a strong emphasis on traumatic brain injury (TBI) 🧠💥, neurodegeneration 🧬, neurogenesis 🌱, and molecular neuroscience. His work explores small molecule therapies, microglial activation, intranasal drug delivery 💊, and microRNA biomarkers, particularly in the context of glioblastoma and stroke. He also investigates brain repair mechanisms, exosomal signaling 📦, and neurotrophin-mimetic compounds. In recent years, his interdisciplinary work has extended to climate impact models 🌍 and machine learning applications 🤖 in brain science, reflecting a comprehensive and innovative research portfolio in translational neuroscience and brain health.

Publication Top Notes

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia

Considering exosomal miR-21 as a biomarker for cancer

The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury

A small molecule p75^NTR ligand protects neurogenesis after traumatic brain injury

MicroRNAs as biomarkers for human glioblastoma: progress and potential

Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers

Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental …

Beneficial effects of minocycline and botulinum toxin–induced constraint physical therapy following experimental traumatic brain injury

Daniel Bikle | Pharmacogenomics | Best Researcher Award

Published on 09/06/202509/06/2025 by Top Pharmaceutical

Daniel Bikle | Pharmacogenomics | Best Researcher Award

Dr. Daniel Bikle, University of California San Francisoco, United States

Dr. Daniel Bikle 🧬 is a distinguished physician-scientist specializing in endocrinology and bone metabolism. He earned his A.B. magna cum laude from Harvard 🎓 and M.D. from the University of Pennsylvania 🏥, followed by a Ph.D. in Biochemistry. Currently a Professor of Medicine and Dermatology at the University of California, San Francisco 🌉, he has held key research and clinical roles since the 1970s. Dr. Bikle is renowned for his groundbreaking work on vitamin D and bone health ☀️🦴. He has received numerous awards 🏆 and serves on editorial boards and international scientific committees worldwide 🌍.

Publication Profile

Orcid

Education

Dr. Daniel Bikle’s impressive academic journey began at Harvard University 🎓, where he earned his A.B. magna cum laude in Biochemical Sciences in 1965. He then pursued his medical degree (M.D.) at the University of Pennsylvania School of Medicine 🏥, graduating in 1969. Following medical school, he completed an internship and residency at Peter Bent Brigham Hospital in Boston 🏨 from 1969 to 1971, gaining valuable clinical experience. Dr. Bikle deepened his scientific expertise by earning a Ph.D. in Biochemistry at the University of Pennsylvania in 1974 🔬, laying a strong foundation for his distinguished career in medicine and research.

Awards

Dr. Daniel Bikle has received numerous prestigious honors throughout his career 🏅. Starting with the Harvard Honorary Scholarship 🎓 in 1961 and multiple National Science Foundation Fellowships 🔬 during the 1960s, he earned several prizes at Harvard and the University of Pennsylvania, including the Henderson Memorial Prize 🏆 and Horatio C. Wood Prize in Pharmacology 💊. He was awarded fellowships by NIH and professional societies such as the American College of Physicians and Molecular Medicine 🩺. His later accolades include the Boy Frame Award 🦴 in 2007 and the Louis V Avioli Founders Award in 2016, recognizing his excellence in bone and mineral research.

Research Focus

Dr. Daniel Bikle’s research primarily focuses on vitamin D biology, its metabolism, and its critical role in bone health, skin physiology, and immune function 🦴☀️🧬. His extensive work explores vitamin D receptor actions, calcium signaling, and their impact on processes like wound healing and stem cell behavior 🩹🧪. He investigates vitamin D’s role in diseases such as long COVID and lymphoma, and how it influences cellular differentiation and mineral metabolism 🦠💉. Dr. Bikle also studies the molecular mechanisms of vitamin D in skin and bone, making his research essential for endocrinology, dermatology, and metabolic bone disease fields.

Publication Top Notes

Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows

The Role of the Vitamin D Receptor in the Epidermal Stem Cell Response to Wounding

Vitamin D and Long COVID: Is There a Role in Prevention or Treatment?

Mediator 1 ablation induces enamel-to-hair lineage conversion in mice through enhancer dynamics

Mediator 1 ablation induces enamel-to-hair lineage conversion through enhancer dynamics

Role of vitamin D and calcium signaling in epidermal wound healing

Ligand‐Independent Actions of the Vitamin D Receptor: More Questions Than Answers

Decreased Calcium-Sensing Receptor Expression Controls Calcium Signaling and Cell-To-Cell Adhesion Defects in Aged Skin

Introduction: Special Issue on Vitamin D Dedicated to the Memory of Anthony W Norman

The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status

Ablation of Ephrin B2 in Col2 Expressing Cells Delays Fracture Repair

Salma Khan | Precision Medicine | Best Researcher Award

Published on 03/06/202503/06/2025 by Top Pharmaceutical

Salma Khan | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Salma Khan, Loma Linda University, United States

Assoc. Prof. Dr. Salma Khan is a distinguished physician-scientist specializing in gynecologic oncology and thyroid cancer research. With a Ph.D. from Kumamoto University 🇯🇵 and faculty appointments at Loma Linda University 🏥, she excels in translational cancer biology. Her groundbreaking work on health disparities, molecular oncology, and thyroid cancer genomics has earned her multiple honors, including the 2024 AACR Women Cancer Research Award 🌟. She actively contributes to the American Thyroid Association, NIH peer review panels, and serves on several journal editorial boards 📚. Dr. Khan is also a dedicated mentor and advocate for diversity in science and medicine .

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Salma Khan began her academic journey with a Higher Secondary Certificate from Govt. M.M. Ali College, Tangail, Bangladesh (1983–1985). 🎓 She earned her MBBS from Gandhi Medical College, Bhopal, India (1986–1991), followed by an internship at Hamidia Hospital (1991–1992). 🏥 Dr. Khan completed her residency in Obstetrics and Gynecology at IPGMR, Dhaka (1992–1994), and pursued a fellowship at Kumamoto University School of Medicine, Japan (1995–1996). 🌸 Her academic excellence culminated in a Ph.D. in Gynecologic Oncology from Kumamoto University (1996–2000), showcasing her dedication to advancing women’s health.

Awards

Assoc. Prof. Dr. Salma Khan has received numerous accolades throughout her distinguished career. She was honored with the Best Mentor Award by BMANA in 2025 (San Francisco), 2023 (Los Angeles), and 2020 (Dallas). 🌟 In 2024, she received the AACR Women Cancer Research Award and the Best Basic Science Research Award in California. 🎗️ A frequent recipient of Travel Awards from the American Thyroid Association (2016–2023), Dr. Khan also earned top honors at scientific meetings and was a keynote speaker in Japan and Korea (2015). 🌍 Her journey began with prestigious academic scholarships in Bangladesh, India, and Japan.

Research Focus

Assoc. Prof. Dr. Salma Khan focuses her research on cancer biology, with a specialized emphasis on exosomes, survivin biology, and biomarkers for early cancer detection, particularly in prostate and breast cancers. Her groundbreaking studies explore how tumor-derived exosomes contribute to cell signaling, apoptosis inhibition, and metastasis, highlighting survivin as a pivotal player and potential diagnostic marker. Dr. Khan’s work intersects molecular oncology and translational medicine, aiming to bridge lab findings with clinical applications. Her contributions are instrumental in advancing non-invasive diagnostic tools and improving cancer prognosis across diverse populations.

Publication Top Notes

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer

Survivin is released from cancer cells via exosomes

Early diagnostic value of survivin and its alternative splice variants in breast cancer

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential

PTEN promoter is methylated in a proportion of invasive breast cancers

Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro

Differential MicroRNA‐Signatures in Thyroid Cancer Subtypes Proteomic profiling of serum-derived exosomes from ethnically diverse prostate cancer patients

Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis (IAP)

LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity

The emerging role of exosomes in survivin secretion

Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis

juan iovanna | Personalized Medicine | Best Researcher Award

Published on 21/05/202521/05/2025 by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity

Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Mario Leporace | Personalized Medicine | Best Innovation Award

Published on 03/05/202503/05/2025 by Top Pharmaceutical

Mario Leporace | Personalized Medicine | Best Innovation Award

Prof. Dr. Mario Leporace, Hospital and University, Italy

Prof. Dr. Mario Leporace is a distinguished Clinical Radiologist at the Department of Nuclear Medicine and Theragnostics, “Mariano Santo” Hospital, Cosenza, Italy. With expertise in oncologic imaging, hybrid and molecular imaging, and cardiovascular radiology, he is renowned for his advanced diagnostic work using X-ray, CT, MRI, PET/CT, and SPECT/CT. He holds a Master’s in Interventional Oncology and has contributed to over 15 peer-reviewed publications. His professional journey spans top institutions in Rome and Cosenza, marking a career dedicated to innovation in radiology and nuclear medicine.

Publication Profile

Scopus

Education

Prof. Dr. Mario Leporace 🎓 is a distinguished expert in interventional oncology and radiology. In 2022, he earned a Master’s Degree in Interventional Oncology from Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, with a thesis on thermal ablation of bone metastases 🔥🦴. From 2001 to 2005, he completed his post-graduate certification in Radiology at the University of Rome “Tor Vergata” 🏥, graduating cum laude with a thesis on hybrid imaging 🧠📸. He also obtained his Degree in Medicine and Surgery from the same university (1995–2001), graduating with top honors and a thesis in vascular imaging 🫀🧬.

Experience

Prof. Dr. Mario Leporace 🩺 has an extensive career in radiology and nuclear medicine, showcasing over two decades of dedicated medical service. Since October 2017, he has been serving in the Department of Nuclear Medicine and Theragnostics at “Mariano Santo” Hospital in Cosenza, Italy ⚛️🏥. From May 2016 to September 2017, he worked at the Department of Radiology, “Annunziata” Hospital 🏨. Earlier, from March 2006 to April 2016, he contributed to the European Hospital in Rome, and concurrently, from November 2005 to April 2016, served at the Aurelia Hospital in Rome 🏛️🔬, strengthening his clinical expertise across institutions.

Research Focus

Prof. Dr. Mario Leporace focuses his research on Thermal Ablation with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) 🔬🧠. His work bridges medical physics and oncological applications, exploring non-invasive treatments that use focused ultrasound energy to thermally ablate tumors with MRI precision guidance 🎯. This technique offers cutting-edge therapeutic possibilities in fields such as oncology, neurology, and women’s health 🧬💡. Prof. Leporace’s contributions advance both the clinical outcomes and technological innovation of MRgFUS, making him a key figure in image-guided therapy, minimally invasive surgery, and cancer treatment research .

Publication Top Notes

The Thermal Ablation with MRgFUS: From Physics to Oncological Applications

Hui Huang | Precision Medicine | Best Researcher Award

Published on 05/04/202505/04/2025 by Top Pharmaceutical

Hui Huang | Precision Medicine | Best Researcher Award

Prof. Dr. Hui Huang, The Eighth Affiliated Hospital of Sun Yat-Sen University, China

Prof. Hui Huang is Vice President of The Eighth Affiliated Hospital of Sun Yat-sen University and a renowned expert in vascular calcification and chronic disease prevention. 📚 He has authored 100+ high-impact papers in journals like Circulation and J Clin Invest, earning honors like ESI Highly Cited and Top 100 High-Value Papers. 🏆 A recipient of China’s Excellent Young Scientists Fund, he directs multiple prestigious laboratories and holds several international patents. 🔬 His research explores metabolic and immune mechanisms in chronic kidney disease and vascular aging.

Publication Profile

Scopus

Education

Prof. Dr. Hui Huang has authored over 100 peer-reviewed papers in prestigious journals such as Circulation (2022, 2023), J Clin Invest. (2021, 2022, 2025), Hypertension (2018, 2021, 2022), STTT (2022–2024), Kidney Int. (2024), and Cardiovasc Res. (2023) 📚. His impactful work has earned distinctions like ESI Highly Cited Papers, Top 100 High-Value Papers, and journal Cover Stories 🏅. A recipient of China’s National Science Fund for Excellent Young Scholars 🎓, he also led the development of the Expert Consensus on Vascular Calcification, offering vital clinical guidance for practitioners in the field of cardiovascular and renal medicine ❤️🩺.

Experience

Prof. Dr. Hui Huang has led more than 13 major research projects, predominantly funded by the National Natural Science Foundation of China (NSFC) 🔬🇨🇳. His groundbreaking work focuses on unraveling the innovative mechanisms behind arterial calcification, chronic kidney disease, and inflammation 🧠🫀. These projects are long-term, high-budget, and scientifically robust, highlighting their critical importance on both national and global stages 🌍💰. Through his pioneering research, Prof. Huang is driving transformative advancements in cardiovascular and renal health, contributing significantly to medical science and improving patient outcomes 🚀🩺.

Research Focus

Prof. Dr. Hui Huang is a leading researcher in biomedical sciences, with a strong focus on cardiovascular disease, immunology, toxicology, and metabolic disorders. Her work spans areas such as inflammation in the central nervous system, myocardial infarction, diabetes-related metabolomics, and environmental health risks like metal toxicity. 🌡️🧠🫀 She also explores digital therapeutics and sex-based differences in disease outcomes, making her contributions highly interdisciplinary. 📊💻 Her research integrates clinical, molecular, and environmental insights to develop novel strategies for disease prevention and treatment. A strong advocate for translational medicine, Prof. Huang bridges lab science with real-world health challenges.

Publication Top Notes

The Innate Immune Sensor Zbp1 Mediates Central Nervous System Inflammation Induced by Angiostrongylus Cantonensis by Promoting Macrophage Inflammatory Phenotypes

Targeted LC-MS/MS method of oxylipin profiling reveals differentially expressed serum metabolites in type 2 diabetes mice with panaxynol

Ellagic acid-enhanced biocompatibility and bioactivity in multilayer core-shell gold nanoparticles for ameliorating myocardial infarction injury

Sex difference in human diseases: mechanistic insights and clinical implications

Effect of plateletcrit and methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on folic acid efficacy in stroke prevention

Digital therapeutics in hypertension: How to make sustainable lifestyle changes

Associations of essential metals with the risk of aortic arch calcification: a cross-sectional study in a mid-aged and older population of Shenzhen, China

Pilar Hernandez Jimenez | Personalized Medicine | Women Researcher Award

Published on 03/04/202503/04/2025 by Top Pharmaceutical

Pilar Hernandez Jimenez | Personalized Medicine | Women Researcher Award

Dr. Pilar Hernandez Jimenez, Hospital Universitario 12 de Octubre, Spain

Dr. María del Pilar Hernández Jiménez 🩺🔬 is a specialist in internal medicine with a focus on infectious diseases. She earned her M.D. from the Universidad de Alcalá (2011) and completed her MIR in Internal Medicine at HU 12 de Octubre (2013-2018). With expertise in HIV, tropical diseases, and antimicrobial resistance, she has contributed to multiple research projects, publishing 21 indexed articles (h-index 9). Currently, she is a Río Hortega researcher at Instituto de Salud Carlos III and a consultant at HU 12 de Octubre. Her doctoral thesis (2024) explores multidrug-resistant Pseudomonas aeruginosa.

Publication Profile

orcid

Education

Dr. Pilar Hernandez Jimenez 🎓 earned her Ph.D. in Health Sciences (2024) from Universidad Complutense de Madrid. She holds a Master’s in Infectious Diseases in Immunocompromised Patients 🦠 and has pursued multiple postgraduate specializations in infectious diseases, tropical medicine 🌍, and HIV 🏥. Her expertise spans critical areas of global health, focusing on combating infectious diseases and improving patient outcomes. With a strong academic foundation and extensive clinical knowledge, Dr. Hernandez Jimenez is dedicated to advancing research and medical practices in infectious disease management, contributing significantly to the field of immunocompromised patient care.

Experience

Dr. Pilar Hernandez Jimenez 🏥 currently serves at Instituto de Salud Carlos III and Hospital Universitario 12 de Octubre, where she plays a vital role in infectious disease research and hospital consultations. With extensive experience in leading studies on infectious diseases 🦠, she has contributed significantly to COVID-19 research 🦠, HIV studies 🏳️‍🌈, and infection management in immunocompromised patients 🤝. Her work bridges clinical practice and research, enhancing patient care and public health strategies. Through collaboration with top medical institutions, Dr. Hernandez Jimenez continues to make a meaningful impact on global health and infectious disease management.

International Exposure

Dr. Pilar Hernandez Jimenez 🌍 has gained extensive international exposure through Erasmus and MIR training in Spain 🇪🇸 and France 🇫🇷, enriching her expertise in infectious diseases. Her global collaborations extend to Brazil 🇧🇷, where she conducted research at Fundação de Medicina Tropical Doutor Heitor Vieira Dourado 🦠, contributing to advancements in tropical medicine and infectious disease management. These international experiences have allowed her to engage with diverse healthcare systems, collaborate with leading researchers, and enhance her medical practice on a global scale. Dr. Hernandez Jimenez continues to foster cross-border medical innovation and research excellence.

Research Focus

Dr. María del Pilar Hernández-Jiménez is a distinguished infectious disease researcher 🦠 specializing in prosthetic joint infections, multidrug-resistant bacteria, and antimicrobial treatments 💊. Her research focuses on periprosthetic infections, Pseudomonas aeruginosa, carbapenemase-producing Klebsiella pneumoniae, and infections in immunocompromised and transplant patients 🏥. She has contributed significantly to clinical microbiology, antimicrobial resistance, and infection control 📊. Dr. Hernández-Jiménez’s work extends to COVID-19-related infections and innovative treatments for latent tuberculosis in transplant recipients 🌍. Her extensive collaborations and impactful publications highlight her global influence in infectious disease research 🔬.

Publication Top Notes

Periprosthetic Infection of Transfibular Ankle Arthroplasties Managed with Implant Retention: Anatomical Limitations of Surgical Debridement

Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review

Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection

Enhancing screening adherence for strongyloides infection in latinx inpatients with COVID-19: a local protocol implementation study.

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Published on 03/04/202503/04/2025 by Top Pharmaceutical

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[¹⁸F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial

2-[¹⁸]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Published on 11/03/202511/03/2025 by Top Pharmaceutical

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. KYU SHIK MUN, Cedars-Sinai Medical Center, United States

Assist. Prof. Dr. Kyu Shik Mun is a distinguished researcher in cystic fibrosis (CF) and biomedical engineering 🧬. As a Principal Investigator and Co-Director, he has led groundbreaking projects on CF-related diabetes, organ-on-a-chip models, and personalized CF therapy 🏥. His work, funded by organizations like the Cystic Fibrosis Foundation and Vertex Pharmaceuticals, has yielded significant patents and high-impact publications 📑. With 733 citations, an h-index of 10, and an i10-index of 10, Dr. Mun continues to drive innovations in CF research, bridging biomedical science and translational medicine 🔬.

Publication Profile

Google Scholar

Professional Background

Assist. Prof. Dr. Kyu Shik Mun earned his Ph.D. in the Materials Science and Engineering Program at the University of Cincinnati 🎓. In 2016, he joined the Cystic Fibrosis Research Center at Cincinnati Children’s Hospital, where he pioneered a microfluidic-based organ-on-chip program from scratch 🏥🧬. His groundbreaking research focused on studying cystic fibrosis and related disorders. In 2021, he was promoted to Assistant Professor at Cedars-Sinai 🏆, where he continues to advance in vitro cell culture models using organ-on-chip technology and 3D bioprinting 🖨️🔬, contributing to innovative solutions in biomedical research and personalized medicine.

Awards

Assist. Prof. Dr. Kyu Shik Mun has received numerous prestigious honors and awards throughout his academic and professional journey 🎖️. He was awarded multiple Outstanding Grade Scholarships at Gangneung National University 🏅 (2000–2009) and recognized for excellence with department and presidential awards 🏆. His achievements include a scholarship from the Korean Broadcasting System 📺 and the Korea Research Foundation 🌏. During his Ph.D. at the University of Cincinnati, he earned a University Graduate Scholarship 🎓 (2010–2014). His research has been recognized by the American Gastroenterological Association and the Cystic Fibrosis Foundation 🧬, receiving multiple Best Abstract and Early Career Investigator awards (2017–2024) 🥇.

Experience

Assist. Prof. Dr. Kyu Shik Mun has been actively involved in non-clinical teaching, contributing to journal clubs and lab mentoring 📚🎤. He has delivered key presentations on organ-on-a-chip technology 🧬, including talks at Cincinnati Children’s Hospital (2020) and Cedars-Sinai (2021) 🏥. His mentorship spans postdoctoral fellows, research associates, and Ph.D. students, guiding projects in 3D bioprinting 🖨️ and patient-derived lung-on-a-chip models 🌬️. Since 2016, he has mentored 15 summer and rotation students—including high school, college, Ph.D., and MD candidates—on fabricating organ-on-a-chips and culturing cells, fostering the next generation of biomedical researchers 🔬.

Research Focus

Assist. Prof. Dr. Kyu Shik Mun’s research primarily focuses on nanotechnology 🧪, biosensors 🧫, and biomedical engineering 🏥. His work spans optical interferometric biosensors for label-free detection, organ-on-a-chip models for diseases like cystic fibrosis 🫁, and TiO₂ nanotube arrays for applications in solar cells ☀️ and photocatalysis. He also explores drug discovery 💊 by targeting molecular pathways in cystic fibrosis and related disorders. His interdisciplinary research integrates materials science 🏗️, biophysics ⚛️, and microfluidics 🔬 to develop innovative medical technologies, aiming to advance precision medicine 🎯 and renewable energy solutions 🌱.